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Abstract
Opportunities for the detection, prediction, and treatment of breast
cancer exist at three biological levels: systemically via the blood, at
the whole organ level, and within the individual ductal lobular
structures of the breast. This review covers the evaluation of
approaches targeted to the ductal lobular units, where breast
cancer begins. Studies to date suggest the presence of 5 to 12
independent ductal lobular systems per breast, each harboring
complex cellular fluids contributed by local and systemic
processes. New techniques for accessing and interrogating these
systems offer the potential to gauge the microenvironment of the
breast and distill biological risk profiles.
Introduction
All breast cancer originates in the lining of the ductal lobular
units [1]. Most pathologists who have studied breast cancer
through the whole organ technique have demonstrated that
the majority of lesions are multifocal within the confines of
one ductal system [2-5]. The most elegant example was
Roland Holland’s [6] classic paper describing 82 meticulous
dissections of mastectomy specimens in which all but one
showed contiguous disease. This has led to the general belief
that most breast cancers arise in one ductal system. Although
this suggests that the ductal lobular system is the most
important anatomical unit in breast cancer development,
there has been little interest until recently in its exploration.
The recent development of techniques to access the ductal
systems, including catheters for cannulation and endo-
scopes, as well as new analytical approaches to the ductal
fluid, have led to a renaissance of interest in this area [7].
Anatomy of the ductal systems
Although most surgical textbooks state without attribution
that there are 15 to 20 ductal openings on the nipple, no
scientific source for this pronouncement has been identified.
This lack of hard data is confounded by an absence of
conformity in terms and definitions. Before the potential for
the intraductal approach can be evaluated we must define
what is meant by a ductal system, and describe the limited
data that exist. To most pathologists, imagers, and clinicians,
a breast ductal system or lobe is a unit consisting of an
opening on the surface of the nipple leading to a lactiferous
duct, which branches into segmental and terminal ducts that
end as lobules. The first question then, is how many of these
lobes or ductal systems are there in the average breast?
The best study dates back to 1841 when Astley Cooper [8]
injected wax through the nipple at autopsy in an attempt to
outline the anatomy of the milk ducts (Figure 1a). He
described being able to inject at most 12 lactiferous ducts,
and more commonly 7 to 10 per nipple. Love and Barsky [9]
observed over 200 lactating women in order to map milk duct
orifices and identified an average of 5 to 9 openings. Teboul
and Halliwell [10] reported on over 6,000 ultrasound studies
of the breast ducts and described 5 to 8 ‘milk pores’ in the
nipple. Finally, Ramsay and colleagues [11] studied 21
lactating women with ultrasound and described 6 to 12 main
ducts.
What then is the source of the 15 to 20 figure commonly
quoted? Cooper, Sartorius and colleagues [12] and Dietz
and colleagues [13] have all described additional non-
arborizing structures accessed through the nipple, varying
from 1 to 4 cm in length and independent from the lobes.
Although each author has given these structures a different
name (tubercles, sebaceous glands, rudimentary ducts, or
atrophic ducts), their descriptions are identical (Figure 1c,d).
These structures appear identical to lactiferous ducts when
seen behind the nipple in cross section, but do not function
as such due to their lack of lobules. In addition to the two
types of structures accessible from the nipple (true ducts and
rudimentary ducts) Going and Moffat [14] identified other
tubular structures in their extensive three-dimensional
reconstruction of a nipple. They described numerous
structures tapered down to a minute lumen at their origin
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from the deep aspect of the nipple. Although they appeared
as ducts in cross section, they did not exit the nipple. Since
they did not trace these structures into the breast, it is not
clear what they represent, or if they extend distally into the
breast parenchyma. Ohtake and colleagues [2] used a
subcutaneous mastectomy as the basis of their computerized
three-dimensional reconstruction and described 16 ductal
systems correlating with the 16 collecting ducts at the nipple.
Although it is difficult to determine from their computerized
models whether some of the structures might be rudimentary,
they vary in size and extent. This variability was confirmed
recently by Going and Moffat [14], whose computerized
reconstruction of a breast showed a variation in size of the
lobes, with the largest six ductal systems constituting 75% of
the breast volume (Figure 1b).
Another issue, brought up by Ohtake and colleagues’ study
[2], is whether ductal systems anastomose with each other.
Cooper stated definitively that he did not find evidence of this
in his dissections. Love and colleagues [9] and Going and
Moffat also showed no evidence of anastomoses. It is
certainly possible that the definition of a single ductal system
may differ in these studies, with all connecting branches
considered part of one system in some reports and part of
two anastomosing systems in others.
Thus, one explanation for the discrepant observation of 5 to 9
versus 15 to 20 ducts may be the additional tubular structures
that mimic the appearance of ducts behind the nipple, but do
not contribute significantly to the ductal lobular infrastructure
of the breast. The nature of these additional structures and
their role in breast physiology and pathology has yet to be
described. Collectively, these data suggest that there are 5 to
12 significant, independent, arborizing lactiferous ductal
systems, each of which cover a finite portion of the breast
geography, and can be assessed from the nipple.
Physiology
The limitation in knowledge regarding the anatomy of the milk
ducts extends equally to their physiology. Sampling of nipple
aspirate fluid (NAF) from the nipple through massage and a
suction device was first reported by Papanicolou and
colleagues in 1953 [15]. Since then many researchers have
analyzed this fluid and found that it has a complex
composition with distinctive biochemical and cellular features.
Petrakis [16] did the most extensive analysis of NAF and
identified a variety of cells, proteins, fatty acids and hormones
(Table 1). An important question concerns the degree to
which these constituents are contributed to breast fluids via
passive versus active processes in the non-lactating breast.
Reproductive hormones have been the best studied in this
regard because of their association with breast cancer [17].
Many researchers have noted that the concentrations of
estrogens in breast fluids are significantly higher than in serum,
with little variation with the menstrual cycle or menopause
[18,19]. Since breast epithelial and stromal cells have the ability
to synthesize estrogen through aromatase or sulfatase, and the
ductal fluid contains estrogen precursors, it has been
hypothesized that local synthesis is one means of generating
elevated estrogen levels in ductal fluid [20]. Chatterton and
colleagues [21] demonstrated that estrogen precursors were
more abundant in breast fluids than estrogen itself, giving some
support to this hypothesis. They also showed, however, that
altered hormone levels in association with oral contraceptive
pills or hormone replacement therapy are reflected in the fluid
after several days, suggesting that there is some diffusion and
concentration going on as well. Interestingly both hormones and
cholesterol levels decline following pregnancy. These lower
levels persist for several years and then gradually rise to pre-
pregnancy levels, suggesting a more complex process [22].
It has also been suggested that each ductal compartment is a
stagnant pond with little fluid exchange. As with milk, both
nicotine and continine have been found in the ductal fluid of
smokers [16]. There is at least some evidence for two way
exchange, however, since intraductal water soluble contrast
material is completely absorbed within 15 to 20 minutes [12].
Fluid sampling techniques
NAF is usually obtained through massage and a simple
suction device. Although this is successful in 80% of non-
Figure 1
Ductal systems of the breast. (a) Ductal systems as depicted by Astley
Cooper (1841). (b) Computer reconstruction of ductal systems as
depicted by James Going and colleagues (2004; copyright the
Pathological Society of Great Britain and Ireland; reproduced with
permission granted by John Wiley and Sons Ltd on behalf of the
PathSoc). (c) ‘Tubercles’ as depicted by Astley Cooper (1841). 
(d) ‘Tubercle’ as depicted by Otto Sartorius (1972).Page 3 of 10
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lactating women, it is usually elicited from only one or two
ducts. In an attempt to better access the whole breast,
technologies for duct cannulation, including catheters and
ductoscopes, have been developed. The first reported
lavage, referred to as a ‘rinse’, was performed by LeBorgne
[23] in Uruguay in 1953. He dilated the ducts, instilled saline,
and then massaged fluid out manually. Sartorius and
colleagues [12] combined lavage with contrast ductography
to collect the fluid as NAF after imaging. Love developed an
intraductal catheter, which used a double lumen to maintain
the patency of the duct while lavaging it [33]. These first-
generation devices have allowed proof of principle.
Most breast cancers are thought to arise from the junctions of
the terminal ductal lobular units of the mammary tree, and
evidence suggests that lavage procedures are capable of
delivering fluid to, and harvesting cells from, these regions of
the gland. Several studies involving the intraductal delivery of
dyes to demarcate the path of lavage fluids have demon-
strated permeation of the lobular-alveolar portion of the ductal
systems [24-26]. Moreover, the procedure has collected
lavage cells exhibiting cytological features of lobular carcinoma
in situ (LCIS) from a patient with pathology-confirmed LCIS
[24]. In addition, lavage study participants have reported
feeling the cooler (room) temperature of the lavage saline
circulating within chest wall and axial regions (unpublished
observations). Collectively, these data suggest that epithelial
cells can be collected from the terminal reaches of the
mammary tree, and that these samples can be used to detect
malignant cells in a subset of women with breast cancer,
albeit with low sensitivity.
The technology is not without its limitations, however. One
technical challenge is that it is not always possible to tell
whether a duct has been perforated in the process of
cannulation. Thus, some lavages may actually represent a
sampling of stroma rather than ductal fluid. In addition, it is
currently not possible to correlate the findings in ductal fluid
with the anatomy of the structure being lavaged (true ductal
system, rudimentary, or atrophied duct). Lavaging under
direct vision with a ductoscope [27,28] can help with these
distinctions but is time consuming, and appropriate scopes
are not readily available. New devices currently in develop-
ment will be able to identify all the nipple orifices, differentiate
between them, and facilitate efficient cannulation, allowing
the field to progress more rapidly.
Origins of ductal fluid
Although many assumptions have been made about the
pathophysiology of NAF, it is still not clear whether it
represents a systemic or local process, or both. The
epidemiology of NAF production would suggest a systemic
process [29]. It is more commonly elicited from women aged
35 to 50 years, of non-Asian ethnic origin, who experienced
early age of menarche, and who have lactated. Moreover,
reductions in NAF yield are associated with selective
estrogen receptor modulators and oophorectomy [30,31].
This would suggest that systemic hormonal stimulation of the
breast leads to NAF production, but does not explain why
only a few ducts produce it.
Some insight can be gained by looking at the categories of
spontaneous nipple discharge, which can originate due to
local and systemic influences (Table 2). It is certainly possible
that as with pathological discharge, some NAF is systemic in
origin while other types represent local pathology. Sanchez
and colleagues [32] used polyacrylamide gel electrophoresis
to analyze NAF protein banding patterns and delineated two
Available online http://breast-cancer-research.com/content/8/2/206
Table 1
Partial listing of nipple aspirate fluid constituents
Proteins Immunoglobulins Fats Hormones Electrolytes Cells
Alpha 1 lipoprotein IgA Lauric Prolactin Sodium Epithelial
Alpha 1 acid glycoprotein IgM Myristic Estrone Potassium Myoepithelial
Alpha 2 macroglobulin IgG H chain Myristoleic Estradiol Chloride Macrophages
Alpha 2 HS glycoprotein IgG L chain Palmitic DHEAS Calcium Neutrophils
Alpha 1 antitrypsin IgE Palmitoleic Progesterone Phosphate Lymphocytes
Trypsin IgD Cholesterol Growth hormone Mast Cells
Beta liprotein Cholesterol epoxides Testosterone Erythrocytes





DHEAS, dihydroepiandrosterone sulfate; EFG, epidermal growth factor; TGF-α, transforming growth factor-alpha.types. One was more similar to milk, and was found in women
who had given birth in the last four years or were on oral
contraceptives. This type was also more common in women
with breast cancer. The other type closely resembled cyst
fluid with regard to color and components, and was more
common in women with benign disease. Other studies have
demonstrated intraductal papillary processes as the source
of atypical cells in NAF, suggesting that local as well as
systemic factors influence NAF production, both of which
need to be taken into account in our thinking.
Initially, the presumption was made that the duct that
secreted most actively and, therefore, was most readily
accessible, would be the ‘sentinel’ duct, representing the
status of the breast [33]. In fact, if NAF represents a field
defect within the whole breast, one would expect that
sampling any duct with NAF in a breast with cancer would
demonstrate atypical cells. Recent studies by Khan and
colleagues [25] and Brogi and colleagues [24] have
demonstrated that this is not the case. Another assumption
was that the fluid yielding ducts would be the ones most likely
to harbor atypical and malignant cells. On the contrary,
several investigations [34-36] have demonstrated atypical
cells in non-discharging ducts at a rate similar to their
incidence in discharging ducts, and Khan and colleagues
[37] showed that most ducts with ductal carcinoma in situ
(DCIS) did not produce NAF. These findings are not
surprising since spontaneous serosanguinous or watery
discharge represents in situ or invasive cancer only about 5%
of the time. Much of the data generated from the analysis of
NAF fluid and cancer risk may be a result of pooling fluid from
several different pathological mechanisms, potentially in the
same breast. Current biomarker and proteomic analysis may
give further insight into this situation.
In fact, the microenvironment of each duct may be distinct with
regard to many properties. Khan and colleagues [35] have
shown different estrogen and estrogen precursor levels in
different ducts. Figure 2 shows NAF from several ducts in one
nipple and the different colors of secretion suggest that indeed
the fluid from separate ducts has distinct properties. Our
unpublished observations have suggested independence and
variability between ducts, but as with Khan and colleagues’
data, these findings were obtained with lavage. When doing
lavage there is always a risk of unidentified perforation, which
would cloud the data. A critical goal is to define interductal
variation at the genetic, biochemical and cellular levels within
the normal and diseased breast. We are currently doing a
lavage study using ductoscopy to confirm the anatomy and
comparing hormone, protein, cell and biomarker levels in at
least three ducts per woman in an attempt to answer this
question. It does appear that cytology is not the same in all the
ducts, and it is certainly possible that some ductal contents are
local, whereas others relate to the whole breast.
Identification of breast abnormalities
The evaluation of intraductal approaches for detecting
abnormalities has been based on the prevailing model of
breast cancer progression, in which epithelial cells lining the
ductal lobular systems progress through successive stages of
hyperplasia, atypical hyperplasia, carcinoma in situ
(DCIS/LCIS), and invasive breast cancer. The mammary gland
is a renewal tissue that exfoliates an unknown proportion of its
epithelial cells into the glandular lumina. An initial assumption
underlying intraductal approaches has been that cells
representing each stage of breast cancer progression are
shed into the ductal systems, and are accessible for
collection. In keeping with the cervical PAP smear paradigm,
cytology evolved as the ‘gold standard’ for the evaluation of
breast fluid abnormalities, which have generally been
classified according to a five-point scale consisting of ICMD
(insufficient cells to make a diagnosis), benign, mildly or
markedly atypical, and malignant categories. Over the years
several paired NAF and lavage studies have been performed
to evaluate the correlation of these cytological classifications
with their histopathological counterparts.
Breast Cancer Research    Vol 8 No 2 King and Love
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Table 2
Types of spontaneous discharge
Types of spontaneous discharge
Galactorrhea Pathological Physiological
Characteristics Milky Sero-sanguinous or watery Colored, opalescent 
Extent Bilateral One duct Multiple ducts
Color Uniform Variable in different ducts: green, 
brown, yellow, etc.
Etiology Physiological/pathological galactorrhea  Intraductal proliferation (papilloma,  Physiological, duct ectasia, 
(increased prolactin) DCIS, carcinoma) duct ectasia microcysts
Origin of process Systemic Local Multiple ducts in one or both breastsIn a pioneering study, King and colleagues [38] detected
atypical NAF cytology in 54% and 70% of benign and breast
cancer cases, respectively, diagnosed with histological atypical
proliferative disease, demonstrating a strong association
between the presence of cytological and histological atypia.
However, correlations for the later stages of breast cancer
progression have been weaker. In the same series, King and
colleagues [12,24,25,39,40] identified malignant NAF cytology
in only 21% of breast cancer cases, and subsequent paired
NAF and lavage studies have revealed similar correlations for
advanced lesions. This trend may be explained in part by
biological factors that determine the availability and collection
of malignant cells in breast fluids.
Early correlative NAF studies by Sartorius and colleagues
[12] failed to diagnose invasive breast cancers larger than
0.8 cm, leading them to suggest that larger lesions may
disrupt the integrity of the ductal system, preventing the
exfoliation of malignant cells into the glandular lumina.
Although extravasation may explain some findings, a review of
subsequent paired NAF and lavage studies reveals the
detection of at least some malignant lesions ranging from 1.5
to 11.5 cm by breast fluid cytology [39-43]. The exfoliation of
tumor cells into the ductal systems may be determined by
additional variables, including abnormal ductal branching and
stromal responses associated with breast cancer
progression. In some studies, atypical breast fluid cytology
has been detected with higher frequency in women with
malignant breast disease, leading to the suggestion that it is a
marker of underlying malignancy [25,38].
In keeping with the hypothesis that pre-invasive lesions would
be more likely to shed cells into the ductal systems, others
have examined the sensitivity of intraductal approaches to
identify DCIS. Krishnamurthy and colleagues [40] detected
malignant NAF cytology in 27% of pure DCIS cases, versus
only 4% of invasive breast cancer cases, and found that the
likelihood of detecting malignant cells was related to the
extent of DCIS within the breast. In contrast, Brogi and
colleagues [24] did not identify malignant cytology in any of
the ductal lavage specimens collected from a series of
mastectomy patients that included 24 breasts containing
DCIS, even when dye administration confirmed lavage was
performed on DCIS-containing ducts.
Khan and colleagues [37], who performed pre-biopsy lavage
on women with mammographically detected microcalcifica-
tions, reported no malignant cytology in association with nine
cases of histopathologically confirmed DCIS. In this study,
ductography was performed to determine the overlap of
lavaged ducts with areas of calcifications associated with
DCIS, and revealed only one instance of overlap (in which the
lavage was classified as benign). Four of the nine DCIS
lesions identified by surgical pathological evaluation in this
study were associated with non-fluid-yielding ducts, which had
not been lavaged. This finding underscores the critical issue of
duct sampling procedures, which historically have been
targeted to the subset of ducts that produce fluid during the
NAF procedure, and thus have led to biased sampling.
The selective sampling of fluid-producing ducts may be one
of the contributing factors underlying the observed low
sensitivity of cytology to detect malignant cells in breast
fluids. As we have noted, the pathophysiological significance
of NAF production during the different stages of breast
cancer progression is not understood, and several recent
studies have indicated that not all ductal systems with
atypical and malignant lesions discharge fluid during the NAF
procedure [24,25,34,36,37]. Such ducts were thus not
sampled during the majority of the paired studies to date.
Although there are a number of complex variables, the above
studies suggest that cytological/histopathological correlations
appear to be stronger for the early stages of breast cancer
progression, particularly for atypical hyperplasia, regarded as
one of the strongest biological risk factors for breast cancer
development [44,45]. Seminal studies by Page and Dupont
demonstrated that a diagnosis of histological atypia via
surgical biopsy is associated with a five-fold increase in
relative risk for future invasive breast cancer development
[44,45]. Cytological atypia diagnosed in fluids obtained by
nipple aspiration and random periareolar fine needle
aspiration is associated with a similar two- to five-fold
increase [46-48]. Because a diagnosis of atypia through a
variety of modalities has consistently been associated with
elevated risk for breast cancer development, it is being widely
evaluated as a risk marker in studies that sample breast
tissue. The ductal lavage technique has consistently revealed
atypical hyperplasia in at least a third of the specimens
Available online http://breast-cancer-research.com/content/8/2/206
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Figure 2
Drops of nipple aspirate fluid from four duct openings display varied
coloration, suggesting that the ductal systems of the breast are
anatomically distinct, and that some breast fluid properties exhibit
interductal variation.collected from all populations of women, including breast
cancer patients [24,25,39], asymptomatic high-risk women
[31,33,34], and healthy volunteers recruited from the general
population (unpublished data). Due to these findings, the
cytological evaluation of ductal lavage specimens has been
heralded as a potential risk assessment tool.
However, there are a number of challenges associated with
the cytological evaluation of ductal lavage samples. To date,
long-term follow-up has not been completed for lavage
studies, and the prognostic significance of atypia detected by
this technique remains undefined. It has been argued that
extrapolation from NAF studies may be inappropriate given
that it is unknown what proportion of the cells collected by
lavage represent naturally exfoliated cells versus intact cells
that are dislodged as the result of the procedure. However,
sampling via the random periareolar fine needle aspiration
technique is independent of naturally occurring exfoliation
and yet reveals a striking association between cytological
atypia and short-term risk [48]. A more critical issue,
associated with the diagnosis of atypia by any modality, is
that despite the elevation of relative risk, the majority of
women diagnosed with histological or cytological atypical
hyperplasia do not develop breast cancer [46,49]. In addition,
most of the women who developed breast cancer in NAF
studies with long-term follow-up had not been diagnosed with
atypia [46]. Additional challenges associated with exfoliative
breast cytology stem from the fact that it is a subjective
procedure often plagued by low reproducibility and poor
inter-observer agreement, particularly with regard to the
classification of atypical hyperplasia [3].
In summary, exfoliative cytology has helped generate proof of
principle for detecting breast cancer-associated abnor-
malities in intraductal fluids, has established intriguing
associations between atypical breast fluid cells and the
presence or risk for developing breast cancer, and has
revealed the heterogeneity of breast fluid cell populations.
However, cytological evaluation has consistently demon-
strated low sensitivity to detect malignancy in NAF and
lavage studies (Table 3), revealed a high degree of
prognostically ambiguous atypical cytology, and failed to
identify the majority of women destined to develop breast
cancer. Some of these limitations may be due to the fact that
atypical hyperplasia is generally a multicentric process, and
can be associated with multiple etiologies.
Biomarkers
To overcome the limitations and challenges of cytology, a
variety of biomarker approaches have been developed to
enable the identification of genetic, epigenetic, and
proteomic alterations in rare cells or soluble molecules in
breast fluids. Figure 3 shows the use of interphase fluores-
cence in situ hybridization (FISH) to detect aneusomy in an
isolated cluster of epithelial cells from a lavage classified as
cytologically benign [39]. While the efficient identification of
such rare events by in situ assays requires the application of
automated imaging systems, infrequent genetic and
epigenetic alterations can be routinely amplified using PCR-
based methods. Methylation-specific PCR (MSP) amplifies
cancer-associated gene promotor methylation events, and
the quantitative multiplex version of this assay (QM-MSP) has
the capacity to detect 1 methylated copy among 100,000
Breast Cancer Research    Vol 8 No 2 King and Love
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Table 3
Comparison of cytology and biomarkers in paired studies
Cytology Biomarker
Fluid collection Sensitivity Specificity Assay Sensitivity Specificity Ref.
Nipple discharge 33% palpable cases NA CEA immunoassay 75% 89% [42]
14% nonpalpable cases NA 80% 89%




ROBE ICMD/no ICMD/no  MSP 85%, 80% [51]
malignant cytology malignant cytology 29% DCIS
Lavage 33% 89% FISH 100% 100% [70]
Lavage 47% 79% FISH 71% 89% [39]
NAF 59% NA MSP 82% 100% [43]
Lavage 31% 100% SELDI-TOF MS 75% NA [41]
Comparison of cytology and biomarkers in paired studies in which breast fluids were collected presurgically from women scheduled for excisional
breast biopsies or mastectomies. Sensitivities reflect the detection of invasive and/or ductal carcinoma in situ (DCIS), except when noted. CEA,
carcinoembryonic antigen; FISH, fluorescence in situ hybridization; ICMD, insufficient cells to make a diagnosis; LOH-PCR, PCR-based loss of
heterozygosity; MSP, methylation-specific PCR; NA, not available; NAF, nipple aspirate fluid; ROBE, routine operative breast endoscopy;
SELDI-TOF MS, surface-enhanced laser desorption and ionization-time of flight mass spectrometry.unmethylated copies [50]. Applied to breast fluids collected
presurgically from breast cancer patients, these assays have
successfully identified cancer-associated methylation events
in a series of samples classified as negative for malignant
cytology or as insufficiently cellular for cytological evaluation
[51]. PCR-based loss of heterozygosity analysis has also
been used to detect allelic losses at the BRCA1 gene in
DNA isolated from the acellular fraction of lavage fluids
collected from BRCA1 mutation carriers [52]. Although no
malignant cytology was identified in the cellular fraction of
these lavages, one of the carriers was subsequently
diagnosed with an invasive breast tumor harboring a loss of
heterozygosity alteration matching that of the lavage sample.
FISH is also being applied to extend the analysis of cytology
slides with the aim of stratifying the diagnostic and
prognostic significance of cytological atypia [53].
While breast fluids may contain diluted quantities of
malignant cells and genetic alterations, they harbor
concentrated mixtures of proteins reflecting the epithelial,
stromal, and infiltrating cell populations of the breast
microenvironment. Two-dimensional gel analyses of nipple
aspirate fluids have revealed the presence of over 1,000
distinct proteins and studies have reported average total
protein concentrations in the mg/ml range [54-56]. Altered
levels of numerous cancer-associated protein markers,
including carcinoembryonic antigen (CEA), prostate specific
antigen (PSA), basic fibroblast growth factor (bFGF), urinary
plasminogen activator (uPA), and human epidermal growth
factor receptor-type 2 (HER-2/neu) have been detected in
nipple aspirate fluids collected from breast cancer patients
relative to healthy control women [42,57-62].
As no single protein is entirely tumor-specific or deregulated
in all tumors, however, there is often significant overlap in the
range of levels present in fluids from diseased versus healthy
subjects. As such, the measurement of any single marker is
sub-optimal and comprehensive approaches are better suited
for interrogating complex breast fluids. To date, several
groups have used SELDI-TOF MS (surface-enhanced laser
desorption and ionization-time of flight mass spectrometry) to
detect breast fluid protein profiles that are unique to breast
cancer patients relative to healthy control women [54,63-69].
The identities of the differentially expressed proteins in these
studies are currently being pursued with the goal of
developing targeted and specific panels of protein markers
useful for detection and risk assessment.
A recent multi-institutional study to develop comprehensive
proteomic approaches for breast fluid analysis has identified
human neutrophil peptides 1 to 3 as candidate biomarkers
[64]. Interestingly, two of the studies that detected different
profiles in breast cancer patients versus healthy women
reported a conservation of proteomic signatures within the
fluids collected from the cancer-bearing and healthy
contralateral breast of the same patient [65,66]. The
biological and/or technical explanations underlying these
intriguing findings are not clear and the technical nuances of
applying proteomic approaches to complex clinical samples
are still evolving. However, because SELDI-TOF is high-
throughput and can be applied to measure the complex
protein mixtures present within the small microliter volumes
easily collected by nipple aspiration, the development of this
application holds enormous promise.
The ability of biomarkers to detect rare cells and soluble
molecules provides significant advantages that are reflected
in direct comparisons with exfoliative cytology. One strategy
to evaluate intraductal approaches for the detection of
abnormalities associated with breast cancer progression has
been the paired study format, in which breast fluids are
collected presurgically by nipple aspiration, lavage, or
endoscopy from women scheduled for excisional breast
biopsies or mastectomies. The paired sets of tissues and
fluids have been evaluated by surgical pathological,
cytological and biomarker analysis to define the sensitivity
and specificity of detecting benign and malignant lesions.
Although not formally validated, preliminary comparisons have
consistently demonstrated superior sensitivities and
specificities for biomarkers relative to cytology (Table 3). The
highest sensitivities were achieved when biomarker analysis
was applied to fluids from lesion-containing ducts confirmed
by endoscopy in a comparison of cytology and FISH to
evaluate lavage specimens for the diagnostic work-up of
spontaneous nipple discharge [70]. This study reported low
sensitivity for cytology, but 100% sensitivity and 100%
specificity for FISH analysis. The comparatively higher
sensitivity of markers in paired studies suggests that even if
abnormal cells are not being shed into, or collected from,
diseased ducts in adequate numbers for systematic detection
by cytology, a variety of biomarkers appear to exhibit the
Available online http://breast-cancer-research.com/content/8/2/206
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Figure 3
Fluorescence in situ hybridization (FISH) analysis of a ductal lavage
specimen collected from a patient with invasive breast cancer and
classified as cytologically benign reveals a rare cluster of cells
exhibiting chromosomal aneusomy [39].required sensitivities to detect rare events signaling evidence
of malignant progression.
Conclusion
At present we do not know the relative extent to which breast
fluid properties reflect developmentally determined ‘field
effects’, systemically controlled breast properties, and/or
changes arising within individual ductal units. An important
goal is to define this through a comprehensive analysis of
interductal variation at the cellular, biochemical, genetic and
proteomic levels in the normal and diseased breast. This will
aid in determining the appropriate anatomic unit that should
be sampled for predicting short- and long-term breast cancer
risk. The value of these approaches will require evaluation
through long-term follow-up studies, such as the multicenter
SEDE (Serial Evaluation of Ductal Epithelium) trial currently
being conducted by Cytyc, Inc., in which high-risk women are
undergoing serial lavage at six-month intervals. This trial was
initiated in 2004 and initial data are expected in 2007 [71].
Despite all the aforementioned gaps in our knowledge
regarding the anatomy and physiology of the ductal systems,
the above studies illustrate the power of biomarkers to detect
abnormalities in breast fluids and to gauge the micro-
environment of the breast, and suggest the potential to distill
biological risk profiles for predicting short- and long-term
breast cancer development. Importantly, 70% of all breast
cancer patients do not exhibit any of the risk factors
incorporated by quantitative historical risk assessment tools
such as the Gail and Claus models [72]. As such, direct
analysis of the breast tissue with non-invasive techniques can
extend risk assessment to the majority of women who are
biologically predisposed to develop breast cancer. For
example, the application of proteomic analyses to breast
fluids may lead to the identification of global profiles reflecting
field effects and/or systemic changes associated with
predisposing systemic variables.
Several SELDI-TOF studies have detected different breast
fluid profiles for breast cancer patients versus healthy control
subjects. That these changes reflect global patterns
associated with predisposition or early breast cancer
progression is suggested by the fact that the differences are
not detected between the diseased and healthy breasts of
cancer patients. Detection of these early patterns would not
rely on targeted sampling, as all ducts would be expected to
harbor the changes. Proteomic analysis of easily obtainable
NAF samples could potentially be used as a screening tool to
identify women with elevated long-term risk. These women
would then become candidates for heightened surveillance
and/or more extensive ductal explorations with lavage and
biomarker analysis to identify and track progression within
specific ductal systems and even intraductal therapy.
The intraductal approach to the breast offers the opportunity
to study the biology and tumorigenesis of the human breast
from a new perspective. Although the clinical and scientific
applications of the approach are currently hindered by basic
gaps in our understanding of the anatomy and physiology of
the ductal lobular systems, they have significant potential.
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